Cellular identity in hematopoiesis is shaped by coordinated activity of master transcription factors together with chromatin remodeling complexes. This review consolidates recent findings that the Runx1–Gata2 axis is a central regulatory module that directs lineage specification and supports self-renewal in hematopoietic stem and progenitor cells. The authors frame Runx1 and Gata2 as key nodes that integrate transcriptional control with changes in chromatin state to establish and maintain hematopoietic programs.
Gata2 is characterized in the review as a pioneer transcription factor capable of engaging closed chromatin. As a pioneer factor, Gata2 can access nucleosome-occluded DNA and initiate regulatory cascades that open chromatin at lineage-relevant loci. This pioneer activity positions Gata2 upstream in the sequence of events that permit subsequent recruitment of co-factors, chromatin remodelers, and other lineage-specific transcription factors necessary for hematopoietic differentiation and stem cell maintenance.
Runx1 is described as participating in the reconfiguration of higher-order chromatin architecture. The review highlights Runx1’s role in reshaping topologically associating domains (TADs) and modulating enhancer–promoter interactions. Through these activities Runx1 helps to establish the three-dimensional chromatin environments that enable precise gene regulation during the endothelial-to-hematopoietic transition and subsequent lineage choices. These architectural functions extend Runx1’s role beyond simple DNA-binding and transcriptional activation.
Mechanistically, Runx1 recruitment is linked to the engagement of chromatin effectors. The review consolidates evidence that Runx1 can recruit chromodomain helicase DNA-binding protein 7 (CHD7) and ten-eleven translocation (TET) family enzymes. CHD7 is implicated in chromatin remodeling activities, while TET enzymes mediate DNA demethylation processes. Together, these recruited effectors provide biochemical mechanisms by which Runx1 influences both nucleosome positioning and DNA modification states, coupling transcription factor occupancy to epigenetic changes that stabilize cell-state decisions.
The review emphasizes how perturbations to the Runx1–Gata2 axis contribute to disease. Disruptive events such as promoter or enhancer hypermethylation, enhancer hijacking, and haploinsufficiency of key factors are described as creating dependencies in malignant cells—termed epigenetic addiction. These epigenetic alterations are linked to the pathogenesis of myeloid neoplasms, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The authors argue that the maladaptive chromatin states sustained by axis disruption promote malignant transformation and maintenance.
Building on mechanistic insights, the review discusses emerging therapeutic approaches that aim to restore appropriate chromatin architecture in malignant clones. Two strategies highlighted are epigenetic editing, which attempts to directly modify DNA methylation or histone marks at specific loci, and super-enhancer targeting, which seeks to disrupt pathologic regulatory hubs that sustain oncogenic transcriptional programs. These approaches are presented as promising directions for reversing pathogenic epigenetic states created by Runx1–Gata2 axis dysfunction.
This review synthesizes current understanding of the Runx1–Gata2 transcriptional axis as a driver of lineage fate through both pioneer factor activity (Gata2) and reorganization of chromatin topology (Runx1). The linkage of Runx1 to chromatin effectors such as CHD7 and TET enzymes provides mechanistic routes from transcription factor binding to durable epigenetic change. Disruption of this axis is associated with an epigenetic dependency in myeloid malignancies, specifically AML and MDS, and motivates targeted strategies like epigenetic editing and super-enhancer intervention. The review consolidates these concepts and underscores their relevance for future basic and translational research aimed at correcting pathogenic chromatin architecture in hematologic disease.
Note: This summary is based solely on the content provided in the sourced PubMed abstract and article metadata (Mallick S, Chakraborty A; Mol Biol Rep. 2026). Details such as experimental data, specific study results, and comprehensive mechanistic evidence were not reported in the provided source text.